About Armata Pharmaceuticals
Armata Pharmaceuticals is a publicly listed company based in Los Angeles (United States) founded in 1989. It operates as a phage therapeutics are developed to target antibiotic-resistant bacteria. The company has 60 employees. Its chief executive is Deborah L Birx. Armata Pharmaceuticals offers products and services including Bacteriophages, Synthetic Phage Platform, and AP-PA02 & AP-PA03. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Bacterial. Its legal entity is ARMATA PHARMACEUTICALS, INC. Its competitors include Spero Therapeutics, Nabriva, Melinta Therapeutics, Iterum Therapeutics and BiomX and 5 more; 10 of its 10 listed competitors have raised funding.
Company details
Armata Pharmaceuticals was founded in 1989 in Los Angeles, United States, within the biotechnology sector. Phage therapeutics are developed by the company to address key antibiotic-resistant bacteria. The lead candidate, AP-SA01, is targeted at Staphylococcus aureus, including multidrug-resistant strains. A pipeline of proprietary synthetic phage candidates is also advanced, such as one for Pseudomonas aeruginosa. Operations focus on therapeutic development for infectious diseases.
- Headquarters Los Angeles, United States
- Employees 60
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website armatapharma.com
- Social LinkedIn
- Legal Name Armata Pharmaceuticals, Inc.
- Annual Revenue$4.9 M (USD)-5.22as on Dec 31, 2025
- Net Profit-$173.8 M (USD)-818.79as on Dec 31, 2025
- EBITDA-$29.69 M (USD)27.78as on Dec 31, 2025
- Latest Funding Round$26.9M (USD), Post-IPO
Apr 2022
- InvestorsCystic Fibrosis Foundation
& 2 more
- Employee Count60
Products & Services of Armata Pharmaceuticals
Armata Pharmaceuticals offers a comprehensive portfolio of products and services, including Bacteriophages, Synthetic Phage Platform, and AP-PA02 & AP-PA03.
Phage-based treatments targeting bacterial infections.
Platform for developing advanced phage therapeutics.
Clinical programs for specific phage therapeutics.
Funding Insights of Armata Pharmaceuticals
- Total Rounds 7
- Last Round Post-IPO — $26.9M
- First Round $2.42M
(Sep 2008)
- Investors Count 3
All 7 funding rounds of Armata Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2022 | $26.9M | Post-IPO | – | – | |
| Feb 2022 | $18.1M | Post-IPO | – | – | |
| Oct 2021 | – | Post-IPO | – | – | |
| Mar 2020 | – | Grant | – | – | |
| Jan 2020 | $25M | Post-IPO | – | – | |
| Feb 2013 | $500,000 | Post-IPO | – | – | – |
| Sep 2008 | $2.42M | Grant | – | – |
3 investors in total: 3 institutional.
Investors in Armata Pharmaceuticals
Armata Pharmaceuticals has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include Cystic Fibrosis Foundation, Innoviva and Military Health.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Respiratory prescription drugs are developed and in-licensed for COPD treatment. | 1996 | inva.com | Brisbane, United States | |
Research funding and support for cystic fibrosis patients are provided. | 1955 | cff.org | Bethesda, United States | |
Administers health care and support for military personnel and operations. | – | health.mil | Falls Church, United States |
Investor details for Armata Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Armata Pharmaceuticals
31 people are tracked at Armata Pharmaceuticals (11 in leadership, 6 in board & advisors, 14 in team); the tracked headcount is 60.
| Name | Role | Group |
|---|---|---|
Deborah L Birx | CEO | Leadership |
Peter Hubbard | Vice President Operations | Leadership |
Jiazhi Wang | Head of Quality Assurance | Leadership |
Mirek Baudys | Scientific Director | Leadership |
Suparna Mishra Sarkar | VP Of Quality | Leadership |
Henry Eran | Sr. Director Quality Control | Leadership |
Jennifer Smith | Chief Of Staff & Lead, Clinical Operations | Leadership |
Julianne Averill | Chief Financial Officer | Leadership |
Pierre Kyme | Chief Business Officer | Leadership |
David House | Senior Vice President Finance | Leadership |
Steven Branston | Director, Armata Pharmaceuticals Australia | Leadership |
Todd C. Peterson | Director | Board & advisors |
Jules Haimovitz | Director | Board & advisors |
Robin C. Kramer | Chair | Board & advisors |
Joseph M. Patti | Director | Board & advisors |
Sarah J. Schlesinger | Director | Board & advisors |
Odysseas Kostas | Member Board Of Directors | Board & advisors |
Caleb Humpal | QC Analyst | Team |
Bhaumik Patel | Sr. Manager, Quality Assurance | Team |
Andrea Lim | Associate Scientist | Team |
11 more people are available in the full profile.
Complete people profiles for Armata Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Armata Pharmaceuticals
Armata Pharmaceuticals is a publicly listed company on the AMEX with ticker symbol ARMP in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date14 Mar 2011
- Listed onNYSEAMERICAN: ARMP
- Listed entityArmata Pharmaceuticals, Inc.
- Exchange sectorHealth technology
- ISINUS04216R1023
- Share price$3.10 (-14.6% on the day) · 2026-10-13
- Market capitalisation$115.3M
- EPS (diluted, trailing year)$-7.59
- Volume (last session)223,201
Financials of Armata Pharmaceuticals
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $4.9M | -$173.8M | -$29.7M |
| 2024 | $5.2M | -$18.9M | -$41.1M |
| 2023 | $4.5M | -$69.0M | -$39.9M |
| 2022 | $5.5M | -$36.9M | -$36.0M |
| 2021 | $4.5M | -$23.2M | -$22.6M |
Detailed financial statements for Armata Pharmaceuticals
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Armata Pharmaceuticals
4 dated milestones of Armata Pharmaceuticals across 33 years, from founding to its latest funding, stage changes and deals.
- Founded Armata Pharmaceuticals is founded.
- Funding First funding round of $2.4M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $26.9M.
Competitors of Armata Pharmaceuticals
Armata Pharmaceuticals has 10 listed competitors in our database, 10 of them funded. They include Spero Therapeutics, Nabriva, Melinta Therapeutics, Iterum Therapeutics and BiomX, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| sperotherapeutics.com | 2013 | Cambridge, United States | $114.7M | 46 | Therapeutics for drug-resistant bacterial infections are developed. | |
| nabriva.com | 2006 | Vienna, Austria | $193.08M | – | Pleuromutilin antibiotics are developed for MDR infections. | |
| melinta.com | 2000 | Morristown, United States | $186M | 290 | Developer of bacterial ribosome-targeting drugs for MDR infections | |
| iterumtx.com | 2015 | Dublin, Ireland | $78.1M | – | Developer of antibiotics for MDR infections | |
| biomx.com | 2015 | Ness Ziona, Israel | $56M | – | Microbiome therapeutics are developed for dysbiosis-linked diseases. | |
| aphage.com | 2016 | Bethesda, United States | $107.87M | 78 | Therapies for multi-drug resistant infections are developed using bacteriophages. | |
| paratekpharma.com | 1996 | Boston, United States | $96.48M | 205 | Therapeutics for antimicrobial resistant infections are developed. | |
| locus-bio.com | 2015 | Raleigh, United States | $67.33M | 74 | Developer of therapeutics for infectious disease and inflammatory indications | |
| vedantabio.com | 2010 | Cambridge, United States | $350.49M | 71 | Therapeutics for infectious and autoimmune diseases are developed. | |
| allecra.com | 2013 | – | $44.44M | – | Antibiotics for multi-drug-resistant bacterial infections are developed. |
Detailed competitors of Armata Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Armata Pharmaceuticals
The website of Armata Pharmaceuticals (armatapharma.com) receives about 5.8K visits a month and ranks #3,278,789 among all websites worldwide, #4,311 in Biotechnology and Pharmaceuticals.
- Monthly visits5.8K
- Unique visitors2.5K
per month
- Global rank#3,278,789
among all websites
- Category rank#4,311
Health · Biotechnology and Pharmaceuticals
- Bounce rate39%
- Pages per visit1.9
- Average visit57 sec
- DevicesDesktop 41% · Mobile 59%
Top companies in Microbiome Therapeutics
10 companies that operate in the same segment as Armata Pharmaceuticals (Microbiome Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Biosolutions and enzymes are developed for biotechnology applications across industries. | 2000 | Bags Sword, Denmark | – | – | – | |
Pendulum is focused on developing advanced probiotic solutions. | 2012 | San Francisco, California, United States | USD 109.5 M | – | 55 | |
Gut microbiome insights, analytics, tests, and therapeutics are provided. | 2019 | Singapore, Singapore | USD 10.5 M | USD 1.37 M | – | |
Microbiome-based therapeutics for skin conditions like eczema are developed. | 2014 | Farmington, United States | USD 37.4 M | – | 12 | |
Engineered microbes are developed as programmable therapeutics for metabolic disorders. | 2013 | Cambridge, Massachusetts, United States | USD 34.4 M | USD 8 K | 1 | |
Therapeutics for infectious and autoimmune diseases are developed. | 2010 | Cambridge, Massachusetts, United States | USD 470.49 M | – | 71 | |
Biological drugs for skin and mucosa wound treatment are developed. | 2016 | Uppsala, Uppsala County, Sweden | USD 4.02 M | USD 1.12 M | – | |
Microbiome-based therapeutics for gut diseases are developed. | 2017 | Edinburgh, Scotland, United Kingdom | USD 72.96 M | – | 65 | |
The gut-brain axis is explored for therapeutic and nutritional innovations. | 2014 | New York, New York, United States | USD 479 M | – | 84 | |
Microbiome therapeutics are developed to address diverse diseases. | 2010 | Cambridge, Massachusetts, United States | USD 257.13 M | USD 789 K | 103 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Armata Pharmaceuticals
Complete news archive for Armata Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Armata Pharmaceuticals
Armata Pharmaceuticals was founded in 1989 and raised its 1st funding round 19 years after it was founded.
Armata Pharmaceuticals is headquartered in Los Angeles, United States. It is registered at Los Angeles, California, United States.
Deborah L Birx is the current CEO of Armata Pharmaceuticals.
Armata Pharmaceuticals has 60 employees.
Annual revenue of Armata Pharmaceuticals is $4.9M as on Dec 31, 2025.
Armata Pharmaceuticals was founded in 1989 in Los Angeles, United States, within the biotechnology sector. Phage therapeutics are developed by the company to address key antibiotic-resistant bacteria. The lead candidate, AP-SA01, is targeted at Staphylococcus aureus, including multidrug-resistant strains. A pipeline of proprietary synthetic phage candidates is also advanced, such as one for Pseudomonas aeruginosa. Operations focus on therapeutic development for infectious diseases.
Armata Pharmaceuticals's top competitors include Spero Therapeutics, Melinta Therapeutics and Vedanta Biosciences.
Armata Pharmaceuticals offers Bacteriophages, Synthetic Phage Platform, and AP-PA02 & AP-PA03.
Yes, Armata Pharmaceuticals is publicly traded on AMEX under the ticker symbol ARMP.
Armata Pharmaceuticals has 3 investors. Key investors include Cystic Fibrosis Foundation, Innoviva, and Military Health.
Armata Pharmaceuticals operates through Armata Pharmaceuticals, Inc..